GB2413764A - Anthelmintic composition - Google Patents

Anthelmintic composition Download PDF

Info

Publication number
GB2413764A
GB2413764A GB0516881A GB0516881A GB2413764A GB 2413764 A GB2413764 A GB 2413764A GB 0516881 A GB0516881 A GB 0516881A GB 0516881 A GB0516881 A GB 0516881A GB 2413764 A GB2413764 A GB 2413764A
Authority
GB
United Kingdom
Prior art keywords
imidazothiazoles
salicylanilides
benzimidazoles
animal
acceptable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0516881A
Other versions
GB2413764B8 (en
GB0516881D0 (en
GB2413764B (en
GB2413764A8 (en
Inventor
Kai Kin Lau
Brian Desmond Ford
John James O'brien
Marcus Holdsworth
Edward Lionel Bruce Whittem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jurox Pty Ltd
Original Assignee
Jurox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30005205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2413764(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jurox Pty Ltd filed Critical Jurox Pty Ltd
Publication of GB0516881D0 publication Critical patent/GB0516881D0/en
Publication of GB2413764A publication Critical patent/GB2413764A/en
Application granted granted Critical
Publication of GB2413764B publication Critical patent/GB2413764B/en
Publication of GB2413764B8 publication Critical patent/GB2413764B8/en
Publication of GB2413764A8 publication Critical patent/GB2413764A8/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to the treatment of anthelmintic infections in animals, and more particularly to compositions that are effective against parasites that are resistant to a wide variety of drug treatments. In a first aspect, the invention provides a synergistic anthelmintically effective composition consisting of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier. In a second aspect, the invention provides a method for treating parasitic infections in an animal, comprising administering to the animal, a synergistic anthelmintically effective amount of a composition which consists of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier. In a third aspect, the invention provides the use of a synergistic anthelmintically effective amount of a composition which consists of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier in the treatment of a parasitic infection in an animal.

Description

GB 2413764 A continuation (72) cont John James O'Brien Marcus Holdsworth
Edward Lionel Bruce Whittem (74) Agent and/or Address for Service: Mewburn Ellis LLP York House, 23 Kingsway, LONDON, WC2B 6HP, United Kingdom
GB0516881A 2003-02-05 2004-02-04 Anthelmintic compostion Expired - Lifetime GB2413764B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003900505A AU2003900505A0 (en) 2003-02-05 2003-02-05 Anthelmintic composition
PCT/AU2004/000126 WO2004069242A1 (en) 2003-02-05 2004-02-04 Anthelmintic composition

Publications (5)

Publication Number Publication Date
GB0516881D0 GB0516881D0 (en) 2005-09-28
GB2413764A true GB2413764A (en) 2005-11-09
GB2413764B GB2413764B (en) 2006-12-20
GB2413764B8 GB2413764B8 (en) 2013-10-16
GB2413764A8 GB2413764A8 (en) 2013-10-16

Family

ID=30005205

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0516881A Expired - Lifetime GB2413764B8 (en) 2003-02-05 2004-02-04 Anthelmintic compostion

Country Status (6)

Country Link
AR (1) AR043044A1 (en)
AU (3) AU2003900505A0 (en)
BR (1) BRPI0407271B1 (en)
GB (1) GB2413764B8 (en)
NZ (1) NZ540391A (en)
WO (1) WO2004069242A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316377D0 (en) * 2003-07-12 2003-08-13 Norbrook Lab Ltd Parasiticidal composition
CA2690111C (en) * 2007-06-29 2011-11-15 Pfizer Inc. Anthelmintic combination
BRPI0820260A2 (en) * 2007-11-09 2015-05-26 Intervet Internac B V Anthelmintic composition and use of composition
AU2010100349B4 (en) * 2009-04-15 2012-03-29 Jurox Pty Ltd Anthelmintic formulation
AR079409A1 (en) 2009-09-07 2012-01-25 Mukhopadhyay Debashis GRANULATED ANTIHELMINTIC PREPARATIONS AND SUNINISTER SYSTEMS
AR081187A1 (en) * 2010-05-12 2012-07-04 Merial Ltd INJECTABLE FORMULATIONS PARASITICIDES OF LEVAMISOL AND MACROCICLIC LACTONS. PREPARATION METHOD. TREATMENT METHOD
PE20141179A1 (en) 2011-06-23 2014-10-11 Bayer New Zealand Ltd AN ANTIPARASITIC COMPOSITION AND METHOD OF TREATMENT
NZ594610A (en) 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
WO2018038623A1 (en) * 2016-08-23 2018-03-01 Donaghys Limited Improvements in parasite treatments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060380A1 (en) * 2000-02-16 2001-08-23 Phoenix Scientific, Inc. A parasiticidal formulation and a method of making this formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060380A1 (en) * 2000-02-16 2001-08-23 Phoenix Scientific, Inc. A parasiticidal formulation and a method of making this formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.P. Louw et al, J. South Afr. Vet. Ass., (1993), 64(2), 71-75 *

Also Published As

Publication number Publication date
AU2003900505A0 (en) 2003-02-20
GB2413764B8 (en) 2013-10-16
NZ540391A (en) 2006-12-22
AU2004210461B2 (en) 2009-12-03
AU2004210461C1 (en) 2017-06-29
WO2004069242A1 (en) 2004-08-19
BRPI0407271B1 (en) 2015-11-10
AU2009201942C1 (en) 2017-06-29
GB0516881D0 (en) 2005-09-28
GB2413764B (en) 2006-12-20
AU2004210461A1 (en) 2004-08-19
AU2009201942A1 (en) 2009-06-04
AU2009201942B2 (en) 2012-02-16
AR043044A1 (en) 2005-07-13
BRPI0407271A (en) 2006-01-31
GB2413764A8 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
BRPI0514420A (en) peptide, variant thereof, or a pharmaceutically acceptable salt thereof, composition, use of a peptide or peptide variant, substrate, and methods of treating or preventing a microbial infection, and treating a wound in an individual
HUP0203870A2 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AR050838A1 (en) PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OPTICAL INFECTION
ATE546169T1 (en) POLYMER COMPOSITIONS CONTAINING BIOACTIVE AGENT, MEDICAL ARTICLES AND METHODS
PE20020237A1 (en) TOPICAL ORAL COMPOSITION
BRPI0518406A2 (en) compositions having high antiviral and antibacterial efficacy
EP2638905A3 (en) Biofilm treatment
BG106366A (en) Moxifloxacin formulation containing common salt
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
WO2005056524A3 (en) Therapeutic agents useful for treating pain
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
GB2413764A (en) Anthelmintic composition
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
IS7517A (en) Compounds used in the treatment of anthrax and prevent lethal effects
WO2007058639A3 (en) Antibacterial agents
ATE447953T1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING LEISHMANIASIS
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
WO2003024996A3 (en) Antibacterial macrocycles
WO2004093876A3 (en) Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
BR0308734A (en) Compound, pharmaceutical composition, use of compound, and method for preventing or treating infection
GT200000185A (en) HYGROMYCIN DERIVATIVES

Legal Events

Date Code Title Description
S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 16 AUGUST 2013

S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: CORRECTIONS ALLOWED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 16 AUGUST 2013 ALLOWED ON 7 OCTOBER 2013

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20231005 AND 20231011

PE20 Patent expired after termination of 20 years

Expiry date: 20240203